# 2025年11月14日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 司奈巴胺辅助治疗未控制局灶性癫痫的早期反应率：一项在多国亚洲人群中开展的随机、双盲、安慰剂对照研究的前瞻性分析。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41230998](https://pubmed.ncbi.nlm.nih.gov/41230998)
**期刊：** Epilepsia
**PMID：** 41230998
**DOI：** 10.1111/epi.70012

### 第一部分 原文与翻译

**英文原标题：** Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double-blind, placebo-controlled study in a multinational Asian population.

**英文摘要原文：**
OBJECTIVE: To examine early responses to cenobamate therapy using prospective data from a dose-response study in Asian patients with focal seizures (YKP3089C035, C035) that employed a titration regimen starting at 12.5 mg/day.

METHODS: In Study C035, adults 18-70 years of age with uncontrolled focal seizures despite treatment with 1-3 antiseizure medications were randomized 1:1:1:1 to receive placebo or adjunctive cenobamate 100, 200, or 400 mg/day. The 24-week double-blind study included an 18-week titration and 6-week maintenance phase. During the first 8 weeks of titration ("early titration phase"), all cenobamate patients received the same dosing regimen: 12.5 mg/day for 2 weeks, 25 mg/day for 2 weeks, 50 mg/day for 2 weeks, and 100 mg/day for 2 weeks. Change in seizure frequency from baseline and responder rates were assessed at these 2-week intervals for combined cenobamate dose groups vs placebo. Analyses were performed on the modified intent-to-treat maintenance (MITT-M) population (≥1 study drug dose and seizure data in the maintenance phase); all patients completed early titration.

RESULTS: Of 519 patients randomized, 446 were included in the MITT-M population (placebo n = 117, cenobamate n = 329). During Weeks 1-2, 3-4, 5-6, and 7-8 of titration, cenobamate patients experienced a median reduction in 28-day seizure frequency of 16.0% (vs 20.0% placebo, p = .81), 27.3% (vs 22.2% placebo, p = .42), 42.9% (vs 15.4% placebo, p = .002), and 55.6% (vs 20.0% placebo, p < .001), respectively. During Weeks 5-6 and 7-8, the 100% responder rates for cenobamate 50 and 100 mg/day were 17.0% (vs 12.8% placebo, p = .29) and 26.7% (vs 8.5% placebo, p < .001), respectively.

SIGNIFICANCE: Statistically significant responses to cenobamate treatment occurred within the first 8 weeks of titration, including a 42.9% median reduction in 28-day seizure frequency (Weeks 5-6) and a seizure-free rate of 26.7% (Weeks 7-8). These data show that substantial seizure reductions occurred in many patients early during cenobamate titration.

**中文摘要译文：**
目的：利用一项在亚洲局灶性癫痫患者中开展的剂量反应研究（YKP3089C035, C035）的前瞻性数据，考察司奈巴胺治疗的早期反应，该研究采用12.5 mg/天的起始剂量滴定方案。

方法：在C035研究中，年龄在18-70岁、虽经1-3种抗癫痫药物治疗但局灶性癫痫发作仍未得到控制的成年患者，被以1:1:1:1的比例随机分配，接受安慰剂或司奈巴胺（100、200或400 mg/天）辅助治疗。这项为期24周的双盲研究包括18周的滴定期和6周的维持期。在滴定期的前8周（“早期滴定期”），所有接受司奈巴胺治疗的患者均采用相同的给药方案：12.5 mg/天，持续2周；25 mg/天，持续2周；50 mg/天，持续2周；以及100 mg/天，持续2周。在这些为期2周的时间区间内，评估了司奈巴胺联合剂量组相对于安慰剂组的癫痫发作频率自基线的变化及应答率。分析在改良意向治疗维持（MITT-M）人群（接受≥1剂研究药物且在维持期有癫痫数据的患者）中进行；所有患者均完成了早期滴定。

结果：在519名随机分组的患者中，446名被纳入MITT-M人群（安慰剂组 n = 117，司奈巴胺组 n = 329）。在滴定期的第1-2周、3-4周、5-6周和7-8周，司奈巴胺组患者的28天癫痫发作频率中位降幅分别为16.0%（vs 安慰剂组20.0%，p = .81）、27.3%（vs 安慰剂组22.2%，p = .42）、42.9%（vs 安慰剂组15.4%，p = .002）和55.6%（vs 安慰剂组20.0%，p < .001）。在第5-6周和第7-8周，接受司奈巴胺50 mg/天和100 mg/天治疗的患者实现癫痫完全无发作的比例（100%应答率）分别为17.0%（vs 安慰剂组12.8%，p = .29）和26.7%（vs 安慰剂组8.5%，p < .001）。

意义：在滴定期的前8周内，司奈巴胺治疗便产生了具有统计学意义的显著疗效，包括在第5-6周时28天癫痫发作频率中位数下降42.9%，以及在第7-8周时达到26.7%的癫痫无发作率。这些数据表明，许多患者在司奈巴胺滴定早期即可实现癫痫发作的显著减少。

### 第二部分 AI 大师评价

本研究通过对一项在亚洲人群中进行的随机对照试验数据进行前瞻性分析，旨在评估司奈巴胺辅助治疗难治性局灶性癫痫的早期疗效。其核心发现是，在低剂量起始并缓慢加量的滴定初期，患者最早在治疗的第5-6周（50mg/天剂量）即可观察到统计学上显著的癫痫发作频率下降。至第7-8周（100mg/天剂量），疗效更为显著，甚至有超过四分之一的患者实现癫痫完全无发作。该研究的价值在于聚焦于药物滴定初期的快速起效特点，为临床医生提供了宝贵的亚洲人群用药证据，证实了司奈巴胺即便在滴定阶段的低剂量下也能迅速为部分患者带来显著的临床获益，这对指导早期治疗决策具有重要意义。

---

## 2. 148例I型神经纤维瘤病患儿的临床与分子特征分析：一项鉴定出14种新发变异的单中心研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225058](https://pubmed.ncbi.nlm.nih.gov/41225058)
**期刊：** European journal of pediatrics
**PMID：** 41225058
**DOI：** 10.1007/s00431-025-06611-w

### 第一部分 原文与翻译

**英文原标题：** Clinical and molecular characterization of 148 pediatric neurofibromatosis type 1 patients: a single-center study identifying 14 novel variants.

**英文摘要原文：**
UNLABELLED: Neurofibromatosis Type 1 (NF1) is a common genetic disorder of childhood, characterized by highly variable expressivity. In addition to café-au-lait spots, it shows multisystemic involvement and may cause skeletal abnormalities, tumor predisposition, and neurodevelopmental delay during childhood. This study aims to investigate the clinical and molecular characteristics of pediatric NF1 patients and to explore possible genotype-phenotype correlations. This study retrospectively evaluated the clinical and molecular findings of 148 pediatric NF1 patients, identifying genotype-phenotype correlations through Next-Generation Sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA) analysis. The mean age at diagnosis was 8.7 years (1 month to 17 years), with a male-to-female ratio of 0.8. Cafe-au-lait spots were the most common finding (99.3%), followed by freckling (46.6%) and Lisch nodules (28.4%). Additional findings included short stature (29.3%), scoliosis (11.4%), neurodevelopmental delay (14.9%), cutaneous neurofibromas (6.8%), plexiform neurofibromas (6.8%), and optic pathway gliomas (6.7%). Magnetic Resonance Imaging revealed T2 hyperintensities in 72.6% of cases. NGS identified NF1 variants in 94.5% of patients, and MLPA detected full-gene deletions in 2 additional cases. With a molecular diagnostic yield of 95.9%, this study identifies 14 novel variants.

CONCLUSION: This study expands the NF1 variant spectrum in children and emphasizes the value of molecular testing for early diagnosis, especially in infants and those with atypical features. Age-stratified clinical data from a large pediatric cohort revealed a potential link between truncating variants and axillary/inguinal freckling. Beyond diagnosis, molecular testing also supports surveillance and genetic counseling, highlighting its clinical utility in managing pediatric NF1.

WHAT IS KNOWN: • NF1 is a well-known genetic disorder with highly variable expressivity. It shows a wide range of clinical findings, even among patients with the same genetic variant. While some specific genotype-phenotype links have been reported, most NF1 variants do not show clear clinical patterns. Certain features, like café-au-lait macules, appear early in infancy, but others, such as freckling or neurofibromas, often appear later.

WHAT IS NEW: • In our pediatric NF1 cohort, axillary/inguinal freckling was found to be significantly more common in patients with truncating variants. For Lisch nodules, cutaneous neurofibromas, tumor presence, and especially T2 hyperintensities, point estimates suggested a non-significant trend toward higher frequencies in the truncating group. This suggests that some features may differ depending on the type of mutation. A total of 14 novel variants in NF1 were identified through NGS.

**中文摘要译文：**
摘要：I型神经纤维瘤病（NF1）是一种常见的儿童遗传性疾病，其特征在于高度可变的临床表现度。除牛奶咖啡斑外，该病还表现为多系统受累，并可能在儿童期引起骨骼异常、肿瘤易感性和神经发育迟缓。本研究旨在探讨NF1患儿的临床和分子特征，并探索可能的基因型-表型关联。本研究通过二代测序（NGS）和多重连接依赖性探针扩增技术（MLPA）分析，回顾性评估了148例NF1患儿的临床和分子学发现，并鉴定了基因型-表型关联。诊断时的平均年龄为8.7岁（范围从1个月到17岁），男女比例为0.8。牛奶咖啡斑是最常见的体征（99.3%），其次是雀斑（46.6%）和利氏结节（28.4%）。其他发现包括身材矮小（29.3%）、脊柱侧弯（11.4%）、神经发育迟缓（14.9%）、皮肤神经纤维瘤（6.8%）、丛状神经纤维瘤（6.8%）和视路胶质瘤（6.7%）。磁共振成像显示72.6%的病例存在T2高信号。NGS在94.5%的患者中鉴定出NF1变异，而MLPA在另外2例病例中检测到全基因缺失。本研究的分子诊断率为95.9%，并鉴定出14种新发变异。

结论：本研究扩展了儿童NF1的变异谱，并强调了分子检测对于早期诊断的价值，特别是对于婴儿和具有非典型特征的患者。来自一个大型儿科队列的年龄分层临床数据显示，截断型变异与腋窝/腹股沟区雀斑之间可能存在关联。除了诊断，分子检测还为疾病监测和遗传咨询提供支持，凸显了其在儿科NF1管理中的临床实用性。

已知信息： • NF1是一种众所周知的遗传性疾病，具有高度可变的临床表现度。即使在携带相同基因变异的患者中，其临床表现也十分广泛。尽管已有部分特定的基因型-表型关联被报道，但大多数NF1变异并未显示出清晰的临床模式。某些特征（如牛奶咖啡斑）在婴儿早期出现，而其他特征（如雀斑或神经纤维瘤）通常出现较晚。

新增信息： • 在我们的NF1患儿队列中，发现腋窝/腹股沟区雀斑在携带截断型变异的患者中更为常见。对于利氏结节、皮肤神经纤维瘤、肿瘤出现，特别是T2高信号，点估计值提示在截断型变异组中存在频率更高的非显著性趋势。这表明某些临床特征可能因突变类型而异。通过NGS共鉴定出14种新的NF1基因变异。

### 第二部分 AI 大师评价

本研究通过对148例I型神经纤维瘤病（NF1）患儿进行回顾性分析，结合了二代测序（NGS）与多重连接依赖性探针扩增（MLPA）技术，旨在全面描绘该疾病的临床与分子谱系。其核心价值在于不仅鉴定出14种新的NF1基因变异，极大地丰富了该疾病的突变数据库，还揭示了截断型变异与腋窝/腹股沟区雀斑之间的潜在关联。这项发现为探索NF1基因型-表型关系提供了新线索，并再次凸显了分子诊断在早期精准识别、指导临床监测及遗传咨询中的关键作用，对儿科NF1的个体化管理具有重要的指导意义。

---

速递结束，祝您工作愉快！